Fig. 3From: Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLCTumor blood flow. TBF values of patients without (Nā=ā8) and with (Nā=ā8) erlotinib therapy (a). Correlation of tumor perfusion (TBF) with V T (b) and [11C]erlotinib K1 (c). Abbreviations: TBF tumor blood flow, V T volume of distribution, Eā without erlotinib therapy, E+ with erlotinib therapy, K1 influx rate constantBack to article page